In the field of chemistry and pharmacology, different researchers have tried to develop treatments consisting of peroxisome proliferator-activated receptors agonists (PPARα and PPARγ), involved in the regulation of lipids, carbohydrates and inflammation, making them therapeutic targets for the treatment of type 2 diabetes, metabolic syndrome, obesity, hyperlipidemias, cardiovascular diseases (atherosclerosis) and neurodegenerative diseases.
These compounds, in particular, the synthetic thiazolidinediones, have proved to be effective for treating some of these conditions, however, some of them failed due to their associated toxicity. Similarly, dual PPARα/PPARγ agonists such as saroglitazar are under surveillance. As a result, the treatment of the affected population is mainly carried out through a cocktail of different drugs such as statins, with their associated adverse effects, and hypoglycemic drugs.
This invention is the solution to toxicity problems of the others PPAR α/γ agonists keeping treatment effectiveness. New compounds, Polycerasoidol and Polycerasoidin derivatives, have been developed to reduce glucose and cholesterol levels.
The main application sector of these compounds would be the pharmaceutical sector, as they can be active principles of drugs for the treatment of type 2 diabetes mellitus, dyslipidemias, metabolic syndrome and associated complications such as cardiovascular, inflammatory diseases. It is a great market due to the percentage of the population affected by these metabolic disorders has increased mainly due to new lifestyle habits (sedentary lifestyle and increased consumption of processed foods).
Researchers are seeking companies to reach license agreements. Technical cooperation with companies or research centers will be considered too, in order to make further progress in drug development. Finally, researchers are seeking investors interested in developing new drugs to carry out clinical trials through financial agreements.